EUVIMEDEUVIMED entdecken
Multizentrische StudieBeobachtungsstudie

The Germline HSD3B1 Variant Is Associated With Response to Androgen Deprivation Therapy and Abiraterone but not With Response to Enzalutamide in Chinese Prostate Cancer Patients

Ruofan Shi, Qijun Du, Chi Yao, Da Huang, Xiaohao Ruan, Adrian Chun Yin Lam, Kuen Chan, Tsun Tsun Stacia Chun, Yuguang Philip Wu, Tsz Yeung Kam iD, Salida Ali, Danfeng Xu und 1 weitere

The Prostate · 2026

DOI: 10.1002/pros.70089 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift The Prostate, 2026. Verfasst von Ruofan Shi und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China. Hauptthemen laut MEDLINE: Phenylthiohydantoin, Androgen Antagonists, Progesterone Reductase, Steroid Isomerases. Die Arbeit nennt 20 Literaturangaben. Gefördert von: This study was supported by Shenzhen-Hong Kong-Macau Science and Technology Program (Category C; SGDX20220530111403024), and Seed Fund for PI Research-Translat….

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

To investigate the role of HSD3B1 germline variant (1245C) in hormone therapy outcomes in Chinese prostate cancer (PCa) patients.

Methods

A multi‐center observational study was conducted enrolling 785 PCa patients who received primary androgen deprivation therapy (ADT) in China. Genotyping of germline variant and survival data were obtained, and clinical outcomes were analysed using Cox regression models.

Results

The median follow‐up time was 31 months. In the entire study cohort, the HSD3B1 variant (1245C) was significantly associated with a shorter time to castration resistance after adjusting for Gleason grade group (dominant model: hazard ratio, HR = 1.62, 95% confidence interval, 95% CI: 1.10–2.40, p = 0.015; additive model: HR = 1.55, 95% CI: 1.12–2.13, p = 0.008). Subgroup analysis ( n = 438) with patients receiving only ADT for HSPC revealed a more significant association between the C allele and ADT failure (dominant model: HR = 2.37, 95% CI: 1.49–3.77, p < 0.001; additive model: HR = 1.93, 95% CI: 1.34–2.79, p < 0.001). Among patients who received next‐generation hormone therapy after ADT failure, the C allele was associated with poorer abiraterone response (HR = 3.02, 95% CI: 1.07–8.50, p = 0.037); however, no significant change of response from enzalutamide was observed (HR = 0.98, 95% CI: 0.27–3.51, p = 0.972).

Conclusions

The HSD3B1 germline variant (1245C) is linked to earlier ADT failure and diminished efficacy of abiraterone but does not affect enzalutamide in the treatment of PCa patients. These findings underscore its potential as a biomarker to guide personalized treatment in PCa.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PhenylthiohydantoinAndrogen AntagonistsProgesterone ReductaseSteroid IsomerasesMultienzyme ComplexesProstatic NeoplasmsAndrostenesHumansMaleNitrilesMiddle AgedBenzamidesAgedGerm-Line MutationChinaTreatment OutcomeProstatic Neoplasms, Castration-ResistantEast Asian People

Stichwörter der Autor:innen

HSD3B1androgen deprivation therapy (ADT)castration resistancegermline variantprostate cancer (PCa)

Substanzen

enzalutamidePhenylthiohydantoinAndrogen AntagonistsNitriles3 beta-hydroxysteroid oxidoreductase-delta(5) 3-ketosteroid isomeraseProgesterone ReductaseSteroid IsomerasesBenzamidesabirateroneMultienzyme Complexes

Autor:innen und Institutionen

  • Department of Urology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
  • Division of Urology, Department of Surgery, School of Clinical Medicine, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong, China.
  • Department of Clinical Oncology, Pamela Youde Nethersole Eastern Hospital, Hong Kong, China.

ORCID-Profile: Tsz Yeung Kam, Rong Na

Förderung

  • This study was supported by Shenzhen-Hong Kong-Macau Science and Technology Program (Category C; SGDX20220530111403024), and Seed Fund for PI Research-Translat…

Zitieren

APA

Shi, R., Du, Q., Yao, C., Huang, D., Ruan, X., Lam, A. C. Y., Chan, K., Chun, T. T. S., Wu, Y. P., Kam, T. Y., Ali, S., Xu, D., & Na, R. (2026). The Germline HSD3B1 Variant Is Associated With Response to Androgen Deprivation Therapy and Abiraterone but not With Response to Enzalutamide in Chinese Prostate Cancer Patients. The Prostate. https://doi.org/10.1002/pros.70089

Vancouver

Shi R, Du Q, Yao C, Huang D, Ruan X, Lam ACY, et al. The Germline HSD3B1 Variant Is Associated With Response to Androgen Deprivation Therapy and Abiraterone but not With Response to Enzalutamide in Chinese Prostate Cancer Patients. The Prostate. 2026. doi:10.1002/pros.70089

BibTeX
@article{Shi2026,
  author = {Shi, Ruofan and Du, Qijun and Yao, Chi and Huang, Da and Ruan, Xiaohao and Lam, Adrian Chun Yin and Chan, Kuen and Chun, Tsun Tsun Stacia and Wu, Yuguang Philip and Kam, Tsz Yeung and Ali, Salida and Xu, Danfeng and Na, Rong},
  title = {The Germline HSD3B1 Variant Is Associated With Response to Androgen Deprivation Therapy and Abiraterone but not With Response to Enzalutamide in Chinese Prostate Cancer Patients},
  journal = {The Prostate},
  year = {2026},
  doi = {10.1002/pros.70089}
}
Kostenlos starten →